Saturday, Oct. 16, 2021 : Issue #1170

TOP STORIES - Diabetes News & Research

Diabetes and COVID-19: Impact 18 Months into the Pandemic

Influence of Metformin Therapy on Mortality in COVID-19

Mortality and Cardiovascular Benefits of SGLT-2 Inhibitors in Type 2 Diabetes

Blood Sugar Fluctuations Lead to Poor Outcomes for Diabetes Patients with Coronavirus

Socioeconomic Status and Obesity in Patients with Diabetes

Hispanic/Latino Ethnicity Associated with Diabetes, Cognitive Decline, & Impairment

Letter from the Editor

We are now 18 months into the pandemic, and many researchers have been able to look at data on the relationship of diabetes and the coronavirus.

This week, our team of interns have taken the time to find the latest information on how diabetes affects Covid outcomes (Laterpay feature), Covid’s effects on diabetes, and what diabetes medications might have a positive effect on Covid outcomes.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

TOP STORIES - Diabetes News and Research

Diabetes and COVID-19: Impact 18 Months into the Pandemic
Systemic review shows sex, age, comorbid conditions, insulin use, and several out-of-range lab predictors on hospital admission, all play a role in COVID-19 severity.

Influence of Metformin Therapy on Mortality in COVID-19
Glucose-lowering medication can influence COVID-19 pathogenesis and could have implications for treating patients with diabetes and COVID-19.

Mortality and Cardiovascular Benefits of SGLT-2 Inhibitors in Type 2 Diabetes
Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?

Blood Sugar Fluctuations Lead to Poor Outcomes for Diabetes Patients with Coronavirus
Blood sugar levels of 70 to 160 mg/dL are considered normal, and anything outside these levels could negatively affect patients.

Socioeconomic Status and Obesity in Patients with Diabetes
Are socioeconomic factors and obesity independently related to diabetes prevalence?

Hispanic/Latino Ethnicity Associated with Diabetes, Cognitive Decline, & Impairment
Long-term diabetes may lead to signs of cognitive decline in Latino patients as early as middle age.

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this newsletter:

Deonna Andrews, PharmD Candidate 2020 of Florida Agricultural & Mechanicalaciences

Alexandria Bartley, PharmD. Caandidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Erica Hicks, PharmD Candidate 2022, South College School of Pharmacy

Oluwatayo Ishola, PharmD. Candidate, South College, School of Pharmacy

Emmanuella Louissaint, PharmD candidate, LECOM College of Pharmacy

Ding Nguyen, PharmD Candidate, University of South Florida Taneja College of Pharmacy

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
www.diabetesincontrol.com

Diabetes In Control
2093 Philadelphia Pike #8370
Claymont, DE, 19703, United States

DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe